Luspatercept

Drug Profile

Luspatercept

Alternative Names: ACE-536

Latest Information Update: 08 Jun 2017

Price : $50

At a glance

  • Originator Acceleron Pharma
  • Developer Acceleron Pharma; Celgene Corporation
  • Class Antianaemics; Disulfides; Immunoglobulin Fc fragments; Peptides; Recombinant fusion proteins
  • Mechanism of Action TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Beta-thalassaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Beta-thalassaemia; Myelodysplastic syndromes
  • Phase II Anaemia
  • Preclinical Sickle cell anaemia

Most Recent Events

  • 01 Jun 2017 Celgene Corporation completes enrolment in the phase III MEDALIST trial for Myelodysplastic syndromes in USA, Belgium, Canada, France, Germany, Italy, the Netherlands, Spain, Sweden, Turkey and United Kingdom
  • 01 Jun 2017 Celgene Corporation completes enrolment in the phase III BELIEVE trial for Beta-thalassemia in USA, United Kingdom, Turkey, Tunisia, Thailand, Malaysia, Taiwan, Lebanon, Israel, France, Canada, Bulgaria, Australia, Italy and Greece
  • 06 May 2017 Updated efficacy data from two phase II trials in Myelodysplastic Syndromes released by Acceleron Pharma and Celgene Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top